CN105315321A - 具有抗肿瘤作用的化合物及其制备方法和应用 - Google Patents
具有抗肿瘤作用的化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN105315321A CN105315321A CN201410311738.XA CN201410311738A CN105315321A CN 105315321 A CN105315321 A CN 105315321A CN 201410311738 A CN201410311738 A CN 201410311738A CN 105315321 A CN105315321 A CN 105315321A
- Authority
- CN
- China
- Prior art keywords
- compound
- toa
- reaction
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 12
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 5
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 5
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 49
- FINHMKGKINIASC-UHFFFAOYSA-N tetramethyl-pyrazine Natural products CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 17
- -1 amino Ligustrazine Chemical compound 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 229940041181 antineoplastic drug Drugs 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 10
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 8
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims description 8
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims description 8
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims description 8
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims description 8
- FMIMFCRXYXVFTA-FUAOEXFOSA-N (4as,6ar,6as,6br,8ar,12ar,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1h-picene-4a-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C FMIMFCRXYXVFTA-FUAOEXFOSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 150000001350 alkyl halides Chemical class 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- 235000015320 potassium carbonate Nutrition 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 201000007270 liver cancer Diseases 0.000 abstract description 4
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 210000004024 hepatic stellate cell Anatomy 0.000 description 17
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 12
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 12
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 12
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 12
- 229940100243 oleanolic acid Drugs 0.000 description 12
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 229940096998 ursolic acid Drugs 0.000 description 12
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229960003720 enoxolone Drugs 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229960001866 silicon dioxide Drugs 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- QGWDYPREORDRIT-LPXJIFNVSA-N 3,11-dioxoolean-12-en-30-oic acid Chemical compound C1[C@@](C)(C(O)=O)CC[C@]2(C)CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@H]4C(=O)C=C3[C@@H]21 QGWDYPREORDRIT-LPXJIFNVSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000003810 Jones reagent Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960004871 acetoxolone Drugs 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940117975 chromium trioxide Drugs 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000013563 matrix tablet Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- RIXNFYQZWDGQAE-UHFFFAOYSA-N oleanolic acid acetate Natural products C12CC=C3C4CC(C)(C)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(OC(=O)C)C1(C)C RIXNFYQZWDGQAE-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HOPVUIZLMIEGMJ-UHFFFAOYSA-N 2-(bromomethyl)-3,5,6-trimethylpyrazine Chemical compound CC1=NC(C)=C(CBr)N=C1C HOPVUIZLMIEGMJ-UHFFFAOYSA-N 0.000 description 1
- QQOMQLYQAXGHSU-UHFFFAOYSA-N 236TMPh Natural products CC1=CC=C(C)C(O)=C1C QQOMQLYQAXGHSU-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 101001072488 Homo sapiens Golgi reassembly-stacking protein 1 Proteins 0.000 description 1
- 101001000691 Medicago sativa Pectinesterase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000907437 Mycoplasma hyopneumoniae (strain 232) Chaperone protein DnaK Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102100036417 Synaptotagmin-1 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QFYHNPYYOBKAQI-UHFFFAOYSA-N n,3,5,6-tetramethylpyrazin-2-amine Chemical compound CNC1=NC(C)=C(C)N=C1C QFYHNPYYOBKAQI-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410311738.XA CN105315321B (zh) | 2014-07-01 | 2014-07-01 | 具有抗肿瘤作用的化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410311738.XA CN105315321B (zh) | 2014-07-01 | 2014-07-01 | 具有抗肿瘤作用的化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105315321A true CN105315321A (zh) | 2016-02-10 |
CN105315321B CN105315321B (zh) | 2018-10-16 |
Family
ID=55243712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410311738.XA Active CN105315321B (zh) | 2014-07-01 | 2014-07-01 | 具有抗肿瘤作用的化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105315321B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107474097A (zh) * | 2016-06-07 | 2017-12-15 | 雷海民 | 具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 |
CN108456239A (zh) * | 2017-02-20 | 2018-08-28 | 雷鹏程 | 具有抗肿瘤作用的化合物ba-x及其制备方法和应用 |
CN108794564A (zh) * | 2018-08-03 | 2018-11-13 | 烟台大学 | 常春藤皂苷元a环并吡嗪衍生物及其制备方法和用途 |
CN108929360A (zh) * | 2017-09-21 | 2018-12-04 | 南京师范大学 | 一类尾接有机导向分子的有机化合物及以该有机化合物为配体的芳基金属配合物 |
CN109867708A (zh) * | 2017-12-01 | 2019-06-11 | 薪火炙药(北京)科技有限公司 | 具有抗肿瘤作用的甘草次酸系列衍生物(tnga-x)的制备方法和应用 |
CN110964078A (zh) * | 2018-09-28 | 2020-04-07 | 薪火炙药(北京)科技有限公司 | 具有抗肺癌作用的常春藤皂苷元类化合物h-x及其制备方法和应用 |
CN111825738A (zh) * | 2019-04-18 | 2020-10-27 | 中检科医药科技(北京)集团有限公司 | 桦木醇衍生物及其亲水性修饰产物,纳米溶液及其制备方法 |
CN112022857A (zh) * | 2020-09-14 | 2020-12-04 | 南通大学 | 白桦脂酸衍生物在制备抗肝病变药物中的应用 |
CN113087693A (zh) * | 2021-04-12 | 2021-07-09 | 云南大学 | 含氮联芳环类化合物、制备方法和应用 |
CN113603743A (zh) * | 2021-08-06 | 2021-11-05 | 南通大学 | 一类具有联合治疗作用的cddo/川芎嗪醇杂合物及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102675401A (zh) * | 2011-03-09 | 2012-09-19 | 雷海民 | 抗肿瘤药物lqc-y的制备及其应用 |
CN103694375A (zh) * | 2013-12-13 | 2014-04-02 | 北京大学 | 一种新的三萜-环糊精共价化合物及其制备方法和用途 |
-
2014
- 2014-07-01 CN CN201410311738.XA patent/CN105315321B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102675401A (zh) * | 2011-03-09 | 2012-09-19 | 雷海民 | 抗肿瘤药物lqc-y的制备及其应用 |
CN103694375A (zh) * | 2013-12-13 | 2014-04-02 | 北京大学 | 一种新的三萜-环糊精共价化合物及其制备方法和用途 |
Non-Patent Citations (4)
Title |
---|
KUO XU ET AL.: "An overview on structural modifications of ligustrazine and biological evaluation of its synthetic derivatives", 《RES CHEM INTERMED》 * |
PENGLONG WANG ET AL.: "Synthesis and biological evaluation of new ligustrazine derivatives as anti-tumor agents", 《MOLECULES》 * |
SULONG XIAO ET AL.: "Synthesis and Anti-HCV Entry Activity Studies of β-Cyclodextrin–Pentacyclic Triterpene Conjugates", 《CHEMMEDCHEM》 * |
王鹏龙等: "新型川芎嗪衍生物的合成及其抗癌活性研究", 《西北药学杂志》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107474097A (zh) * | 2016-06-07 | 2017-12-15 | 雷海民 | 具有抗肿瘤作用甘草次酸‑肉桂酸衍生物(ga‑ca)的制备方法及其应用 |
CN108456239A (zh) * | 2017-02-20 | 2018-08-28 | 雷鹏程 | 具有抗肿瘤作用的化合物ba-x及其制备方法和应用 |
CN108929360A (zh) * | 2017-09-21 | 2018-12-04 | 南京师范大学 | 一类尾接有机导向分子的有机化合物及以该有机化合物为配体的芳基金属配合物 |
CN108929360B (zh) * | 2017-09-21 | 2020-11-20 | 南京师范大学 | 一类尾接有机导向分子的有机化合物及以该有机化合物为配体的芳基金属配合物 |
CN109867708A (zh) * | 2017-12-01 | 2019-06-11 | 薪火炙药(北京)科技有限公司 | 具有抗肿瘤作用的甘草次酸系列衍生物(tnga-x)的制备方法和应用 |
CN109867708B (zh) * | 2017-12-01 | 2021-03-23 | 薪火炙药(北京)科技有限公司 | 具有抗肿瘤作用的甘草次酸系列衍生物(tnga-x)的制备方法和应用 |
CN108794564A (zh) * | 2018-08-03 | 2018-11-13 | 烟台大学 | 常春藤皂苷元a环并吡嗪衍生物及其制备方法和用途 |
CN108794564B (zh) * | 2018-08-03 | 2021-01-19 | 烟台大学 | 常春藤皂苷元a环并吡嗪衍生物及其制备方法和用途 |
CN110964078B (zh) * | 2018-09-28 | 2021-03-23 | 薪火炙药(北京)科技有限公司 | 具有抗肺癌作用的常春藤皂苷元类化合物h-x及其制备方法和应用 |
CN110964078A (zh) * | 2018-09-28 | 2020-04-07 | 薪火炙药(北京)科技有限公司 | 具有抗肺癌作用的常春藤皂苷元类化合物h-x及其制备方法和应用 |
CN111825738A (zh) * | 2019-04-18 | 2020-10-27 | 中检科医药科技(北京)集团有限公司 | 桦木醇衍生物及其亲水性修饰产物,纳米溶液及其制备方法 |
CN112022857A (zh) * | 2020-09-14 | 2020-12-04 | 南通大学 | 白桦脂酸衍生物在制备抗肝病变药物中的应用 |
CN112022857B (zh) * | 2020-09-14 | 2021-10-12 | 南通大学 | 白桦脂酸衍生物在制备抗肝病变药物中的应用 |
CN113087693A (zh) * | 2021-04-12 | 2021-07-09 | 云南大学 | 含氮联芳环类化合物、制备方法和应用 |
CN113087693B (zh) * | 2021-04-12 | 2023-04-25 | 云南大学 | 含氮联芳环类化合物、制备方法和应用 |
CN113603743A (zh) * | 2021-08-06 | 2021-11-05 | 南通大学 | 一类具有联合治疗作用的cddo/川芎嗪醇杂合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN105315321B (zh) | 2018-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105315321A (zh) | 具有抗肿瘤作用的化合物及其制备方法和应用 | |
CN101775059B (zh) | 甘草次酸衍生物、其制备方法及其医药用途 | |
CN102153564B (zh) | 含氮原子的青蒿素二聚体、其制备方法及用途 | |
Lan et al. | Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives | |
CN101812059A (zh) | 一氧化氮供体型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 | |
Tuncay et al. | Synthesis of oleanolic acid analogues and their cytotoxic effects on 3T3 cell line | |
CN103848793A (zh) | β-榄香烯取代哌嗪酰胺类衍生物及其制备和应用 | |
CN102408403A (zh) | 土槿皮酸类衍生物及其制备方法和用途 | |
JP5542930B2 (ja) | ステロール誘導体、並びにそれらの合成及び使用 | |
KR101739083B1 (ko) | 세포 증식성 질환 치료용 플래티넘 화합물, 그 제조방법 및 용도 | |
CN106478760B (zh) | 具有抗肿瘤作用的三帖类衍生物tba-x及其制备方法和应用 | |
CN110156822A (zh) | 一种萘酚-苯硼酸类化合物及其制备方法和用途 | |
CN109897022B (zh) | 含笑内酯衍生物、其药物组合物及其制备方法和用途 | |
Cheng et al. | Synthesis and cytotoxic evaluation of several oleanolic acid–uracil/thymine conjugates | |
CN110028482B (zh) | 布雷菲德菌素a的4-位拼合美法仑类氮芥衍生物及其制备方法和用途 | |
CN104530171A (zh) | 五环三萜类化合物及其制备方法以及该化合物在制备防治肿瘤药物中的应用 | |
CN102250190B (zh) | 一种齐墩果酸皂苷类衍生物、其盐的制备方法及其用途 | |
CN102746212B (zh) | β-榄香烯吲哚衍生物及其制备和应用 | |
JP5748670B2 (ja) | 組成物および使用の方法 | |
CN103724321B (zh) | 一氧化氮和硫化氢供体型苯酞衍生物及其制备方法和用途 | |
CN102731591A (zh) | 一种抗肿瘤、抗病毒的化合物、其制备方法及用途 | |
CN110028480B (zh) | 布雷菲德菌素a的4,7-位拼合美法仑类氮芥衍生物及其制备方法和用途 | |
RU2506085C1 (ru) | Тетраэтил-2-(2,2,6,6-тетраметилпиперидин-4-иламино)-этилен-1,1-бисфосфонат, обладающий противоопухолевой активностью | |
CN103127054B (zh) | 二氢色原酮骨架化合物在制备治疗恶性肿瘤的药物中的应用 | |
CN104098594B (zh) | 生物素-鬼臼毒素酯化衍生物及其药物组合物和其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160325 Address after: 100176 Beijing branch of Beijing economic and Technological Development Zone Street 88 Hospital No. 3 Building Room 1603 Applicant after: 3D MEDICINES, Ltd. Address before: 100102 Department of traditional Chinese medicine, School of traditional Chinese medicine, Beijing University of Chinese Medicine, 6 South Central Road, Wangjing, Beijing, Chaoyang District Applicant before: Lei Haimin |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200630 Address after: Room 703, building 3, No. 100, Jinyu Road, Pudong New Area, Shanghai, 201206 Patentee after: MindI (Shanghai) Pharmaceutical Technology Co.,Ltd. Address before: 100176 Beijing branch of Beijing economic and Technological Development Zone Street 88 Hospital No. 3 Building Room 1603 Patentee before: 3D MEDICINES, Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211028 Address after: 201206 room 703, building 3, No.100, Jinyu Road, Pudong New Area pilot Free Trade Zone, Shanghai Patentee after: MindI (Shanghai) Pharmaceutical Technology Co.,Ltd. Patentee after: MindI biomedical (Shanghai) Co.,Ltd. Patentee after: 3D MEDICINES, Ltd. Address before: 201206 room 703, building 3, No.100, Jinyu Road, Pudong New Area pilot Free Trade Zone, Shanghai Patentee before: MindI (Shanghai) Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160210 Assignee: Sichuan thought Kangrui Pharmaceutical Co.,Ltd. Assignor: MindI (Shanghai) Pharmaceutical Technology Co.,Ltd.|MindI biomedical (Shanghai) Co.,Ltd.|3D MEDICINES, Ltd. Contract record no.: X2022510000043 Denomination of invention: Compounds with antitumor effect and preparation method and application thereof Granted publication date: 20181016 License type: Common License Record date: 20220824 |
|
EE01 | Entry into force of recordation of patent licensing contract |